Peptide Profile
Cagrilintide
Cagrilintide is a synthetic, long-acting amylin analogue. Modeled after the naturally occurring pancreatic hormone amylin, a potent agent for chronic weight management and glycemic control, often paired synergistically with GLP-1 receptor agonists.
1. Chemical Structure and Biochemistry
Cagrilintide is an acylated peptide, meaning its structure is modified with a fatty acid chain.
- Structural Modification: The attachment of a fatty acid diacid moiety allows the peptide to bind tightly to serum albumin in the bloodstream. This prevents rapid renal clearance and enzymatic degradation, drastically extending its half-life to accommodate once-weekly dosing rather than daily administration.
2. Mechanism of Action
Cagrilintide acts as a non-selective agonist at both amylin and calcitonin receptors.
- Satiety and Gastric Emptying: By mimicking amylin, it acts directly on the brain's satiety centers (such as the area postrema) to induce feelings of fullness. It also slows gastric emptying, thereby reducing meal-time blood glucose spikes.
- Glucagon Suppression: It inhibits the postprandial secretion of glucagon, an endogenous hormone that raises blood sugar.
3. Research and Applications
Cagrilintide is at the forefront of advanced metabolic therapies.
- Obesity and Weight Loss: Investigated as a standalone treatment for obesity and in combination therapies (e.g., CagriSema, a combination of Cagrilintide and Semaglutide) to achieve synergistic weight loss that rivals bariatric surgery in clinical trials.
- Type 2 Diabetes: Studied for its ability to lower HbA1c levels without promoting weight gain or hypoglycemia.
Tags:
Cagrilintide
Cargilintide
amylin-analogue
acylated-peptide
calcitonin-receptor-agonist
obesity-research
weight-loss-peptide
CagriSema
delayed-gastric-emptying